

INTRODUCTION AND BACKGROUND

- Hepatorenal syndrome (HRS) is a complication of end-stage renal failure.
- Liver transplantation (LT) remains the only definitive treatment for hepatorenal syndrome.
- The initiation of renal replacement therapy (RRT) in patients with HRS has extremely high mortality rates and has been utilized as a bridge to LT.

STUDY AIM

• We aimed to analyze temporal trends and outcomes of RRT in HRS patients

METHODS

- The National Inpatient Sample (NIS) database from the year 2000 to 2019 was queried for patients to identify HRS patients using ICD codes.
- We used linear regression for continuous variables, the Cochran-Armitage Trend Test for categorical variables with two levels, and the Cochran-Mantel Haenszel Test for categorical variables with more than two levels.
- The p-values of < 0.01 were considered significant.
- Statistical analysis is performed in R (Studio 1.4).

CORRESPONDING AUTHOR

Corresponding Author:

- Maryam Haider Faculty Internal Medicine Residency Program, DMC -WSU Sinai-Grace Hospital, MI
- maryam.haider@wayne.edu



Temporal Trends, Outcomes and Predictors of Mortality in Hepatorenal Syndrome Patients with Renal Replacement Therapy– National Inpatient Sample Analysis 2000-2019 Maryam Haider¹; Tooba Tariq²; Hamid-Reza Moein³, Paul Naylor²; Mutchnick Milton²

¹Detroit Medical Center/Wayne State University School of Medicine, Detroit, MI, USA ²Department of Gastroenterology, Wayne State University School of Medicine, Detroit, MI, USA ³Department of Hepatology and Transplantation, Atrium Health Wake Forest Baptist Medical Center, Charlotte, NC

TABLES

cohort.

race.





RESULTS

- We identified 518,464 patients with HRS, of which 97,037 (18.7%) underwent RRT.
- During 2000 to 2019, HRS-RRT prevalence increased from 11.2% to 19.9% with P < .0001.
- The mortality of HRS without RRT decreased from 55.9% to 23.2% P < .0001, and with RRT decreased from 58.3% to 31.5% P < .0001.
- The mortality of HRS-RRT female patients decreased from 50.5% to 29.1%, males from 62.4% to 33.1%, Caucasians (CAU) from 60.0% to 30.7%, African Americans (AA) from 65.1% to 33.9%, Hispanics (H) from 58.0% to 26.6%, and Asians from 60.1% to 36.2%, all with P < .0001.
- The multivariate analysis showed that older age (aOR:1.89; 99%) CI, 1.18 - 3.03; P < .0001) for 85+, compared to 18-44, AA (aOR: 1.19; 99% CI, 1.03 – 1.37; P < .0001), compared to CAU. Metastatic cancer, cerebrovascular disease, CHF hypertension, seizures, and neurological disorders were significantly correlated with higher in-hospital mortality of HRS-RRT patients.

LIMITATIONS

- The NIS does not identify individual patients, and recurrent hospitalizations appear as distinct observations.
- Inherent design flaws of administrative databases.
- Coding errors when combining ICD 9 with ICD 10
- No information on outpatient population.

LEARNING POINTS

- The mortality of HRS patients decreased over the last two decades. This could be because of availability of newer therapies. HRS patients with RRT have higher mortality than those without RRT, possibly due to the severity of the disease in HRS-the RRT
- RRT does not favor older age, male gender, black and Hispanic